Not exactly. My work focuses on the use of mesenchymal cells to treat brain injuries, primarily stroke. Recently we've been using the exosomes that the MSCs spit out as a proxy for MSC therapy. Exosomes appear to promote recovery in rodents and primates just as effectively as the parent cells themselves. Cell targeting is a difficult thing to pin down, because being ~50-100nm, exosomes are difficult to tag and track with any real precision. To the extent we have been able to track them, they seem to target the microglia in the vicinity of the lesion more than any other cell type. Been doing some mechanistic studies recently trying to probe what exactly the effect of "feeding" exosomes from MSC to microglia is. The "young blood" thing (really young bone marrow) is a side business that sprang out of work that mk and I have done together for many years.